Close Menu

NEW YORK – PerkinElmer announced on Wednesday its Delfia Xpress sFlt-1 kit for predicting preeclampsia has received the CE-IVD mark.

The test can also be used as an aid to diagnose preeclampsia in the second and third trimesters of pregnancy with PerkinElmer's Delfia Xpress PIGF 1-2-3 assay, the Waltham, Massachusetts-based firm said. The addition of sFlt-1 completes its preeclampsia product portfolio, and PerkinElmer said it now offers different solutions for managing the condition during all trimesters.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.